Opinion|Videos|November 13, 2026

Managing Belzutifan Toxicity and Shared Decision-Making in Adjuvant RCC

Desai and Kydd on managing anemia and hypoxia from belzutifan, patient risk-benefit conversations, and sequencing considerations in high-risk adjuvant RCC.

Desai: I absolutely agree with you, and especially on the belzutifan toxicity spectrum. You very rightly pointed out that there are two main toxicities: anemia and hypoxia, or low oxygen saturation. Anemia is seen in up to 12% of patients in this population, and hypoxia a lot less — less than 5%, up to 4.6%.

What do you tell patients in terms of how you manage the anemia in this setting? Because this is a mechanism-based toxicity. How comfortable are you talking about erythropoietin-stimulating agents in this setting, or blood transfusion? There's a lot that goes into the patient conversation prior to starting these drugs. What does that look like?

Kydd: I usually try to lay out all those possibilities that we might need, because sometimes we do need transfusions. I want to keep both of those options open, and I want to make sure patients are aware of that as they're starting to make those decisions. That might be something they're more than willing to take on — again, that's part of the risk-benefit calculus as they're thinking about whether it's worth it for that DFS benefit.

Some people might say they don't feel comfortable going through those additional measures if they have no signs of disease on their scans. Other people are more than willing to take on those possibilities. So it absolutely does need to be a part of the conversation so that they're aware of what might be needed. There are a number of patients that don't require that, so there's a little bit of uncertainty about what each patient will need. Part of it is looking at their current state of health — whether they already have some level of anemia, or any other comorbidities that might make them more likely to have hypoxia or lower pulmonary reserve that would require oxygen support or other measures.

Desai: You're absolutely right. This informed decision-making is so important in this setting. Depending on the risk of recurrence, along with the patient's medical comorbidities — what comorbidities they have, how healthy they are before having a nephrectomy — and obviously at the end of the day, what do the patients really want? Some want everything done, even if there's a very minimal benefit. Others are risk-averse and don't want to do anything. So it's really important to get to the bottom of what the patient's goals of care are and what they actually need.

Any key takeaway points from the study?

Kydd: That risk-benefit calculus is one of the biggest takeaways, because it requires a very nuanced conversation. That's one of the most important things clinicians need to be very comfortable describing to patients, because every patient will look at those risks and benefits a little differently with the evidence we have now. It's also the reason we do need that overall survival benefit, because for many patients that is going to be one of the biggest decision-making points about whether or not they want to move forward with this treatment.

One of the things we consider is that belzutifan is approved for later lines. So as we're looking at both clinical trial evidence and real-world evidence, if we were to hold off on adding belzutifan in this setting — or if some patients are not comfortable with immune checkpoint inhibitors in the adjuvant setting — whether they would be able to receive those agents in a later line is a big question. Crossover in this setting is a big consideration, because the number of patients who don't get belzutifan in the adjuvant setting may ultimately get that same agent or other HIF-2α inhibitors that are in development in the future. That might lead to the overall survival benefit not being seen, because patients are ultimately able to get that drug anyway.

But there might also be patients who, unfortunately, don't get to a first line in the metastatic setting, or a second or third line, in which case that has to be part of the information we present — and part of what they have to take into account. So it's already a nuanced conversation, and it will continue to be quite a challenge in terms of discussing all these details and uncertainties and looking at what the patient most values as they're starting to make these decisions.

Desai: That was really nicely put. That was a quick look between the lines of one practice-changing study — how we interpret the evidence and what it may mean for clinical practice. Thank you all for joining us for this Between the Lines session.

Kydd: Thank you very much. It's been wonderful talking with you.

Desai: It's a pleasure as well. Thank you.


Related to this article